文献速递造血干细胞移植与细胞治疗

西罗莫司联合钙调磷酸酶抑制剂治疗激素耐药/依赖广泛型cGVHD的临床观察

[The clinical observation of sirolimus combined with calcineurin inhibitors for steroid-resistant/steroid-dependent extensive cGVHD].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

该研究纳入27例糖皮质激素耐药/依赖的广泛型cGVHD患者,给予西罗莫司联合环孢素A或他克莫司治疗。随访6个月总反应率55.6%,12个月总反应率59.3%,OS-12为100%,不良反应以1~2级为主,无新增CMV、EB病毒感染。

要点

  • 西罗莫司联合CNI治疗激素耐药/依赖广泛型cGVHD,6个月ORR为55.6%,12个月ORR为59.3%。
  • 该方案对口腔、皮肤、肝脏cGVHD疗效较好,对男供者cGVHD更有效。
  • 不良反应以1~2级为主,无新增CMV、EB病毒感染,适合长期治疗。

核心结论

  • 西罗莫司联合CNI治疗糖皮质激素耐药/依赖广泛型cGVHD疗效及安全性较好,适合cGVHD的长期治疗。

研究设计与样本

  • 研究纳入2015年11月至2019年1月27例糖皮质激素耐药/依赖广泛型cGVHD患者,给予西罗莫司联合环孢素A或他克莫司治疗,观察临床疗效与不良事件。

主要发现

  • 中位服药时间14.2个月,中位随访时间20.1个月(范围12.9~46.1个月)。
  • 随访6个月时CR 3例、PR 12例,ORR为55.6%,PFS-6为88.9%(24/27),OS-6为100%。
  • 随访12个月时CR 5例、PR 11例,ORR为59.3%,PFS-12为62.9%(17/27),OS-12为100%。
  • 亚组分析发现该方案对男供者cGVHD更有效,对口腔、皮肤、肝脏cGVHD疗效较好。
  • 不良反应包括高脂血症11.1%、口腔溃疡7.4%、真菌感染11.1%、肝损伤3.7%,肾功能不全0,无新增CMV和EB病毒血症。

临床怎么用

  • 对于糖皮质激素耐药/依赖的广泛型cGVHD患者,可考虑西罗莫司联合CNI治疗,尤其口腔、皮肤、肝脏受累者。
  • 治疗期间需监测血脂、口腔溃疡、真菌感染及肝肾功能等不良反应。

局限性

  • 本研究为单中心、小样本(27例)临床观察,无对照组,结论需进一步大样本随机对照研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To observe the efficacy and safety of sirolimus combined with calcineurin inhibitor (CNI) in the treatment of glucocorticoid resistant/dependent extensive chronic graft-versus-host disease (cGVHD) . Methods: A total of 27 patients with steroid-resistant/steroid-dependent extensive cGVHD from November 2015 to January 2019 were enrolled and given sirolimus capsules combined with cyclosporine or tacrolimus to observe the clinical efficacy and adverse events. Results: The median duration of medication was 14.2 months and the mean duration was 16.7 months. The median follow-up time was 20.1 months (12.9-46.1 months) . Following the 6-month follow-up, 3 cases achieved complete response (CR) and 12 cases partial response (PR) . The overall response rate (ORR) was 55.6% ; for progression-free survival (PFS) , PFS-6 reached 88.9% (24/27) , and for overall survival (OS) , OS-6 was 100% . At the 1-year follow-up, there were 5 cases of CR and 11 cases of PR, ORR was 59.3% , PFS-12 reached 62.9% (17/27) , and OS-12 was 100% . The subgroup analysis found that the program was more effective for cGVHD in male donors and the target organ analysis had an advantage in the treatment of oral cavity, skin, and liver rejection. Adverse events were observed: hyperlipidemia 11.1% , oral ulcer 7.4% , fungal infection 11.1% , liver injury 3.7% , renal insufficiency 0, and no new CMV and EB viremia. Conclusion: Sirolimus combined with calcineurin inhibitors is effective in treating steroid-resistant/steroid-dependent extensive cGVHD, especially because adverse reactions (renal toxicity, CMV, EBV infection) are low in number, which is suitable for long-term treatment of cGVHD. 目的: 观察西罗莫司联合钙调磷酸酶抑制剂(CNI)治疗糖皮质激素耐药/依赖广泛型慢性移植物抗宿主病(cGVHD)的疗效和安全性。 方法: 选择糖皮质激素治疗耐药/依赖的cGVHD患者,给予西罗莫司联合环孢素A/他克莫司治疗。 结果: ①入组患者27例,男17例,女10例,中位年龄36(19~56)岁。急性髓系白血病13例,急性淋巴细胞白血病4例,慢性髓性白血病4例,骨髓增生异常综合征3例,淋巴瘤1例,再生障碍性贫血1例,阵发性睡眠性血红蛋白尿症1例。HLA全相合同胞或亲缘供者移植14例,HLA全相合无关供者移植2例,HLA不全相合同胞或亲缘供者移植11例。②患者中位服药时间为14.2个月,中位随访时间20.1(12.9~46.1)个月。③随访6个月时,完全缓解(CR)3例,部分缓解(PR)12例,总反应率(ORR)为55.6%,6个月时无病生存率(PFS-6)、总生存率(OS-6)分别为88.9%(24/27)、100%。④随访12个月时,CR 5例,PR 11例,ORR为59.3%,PFS-12为62.9%(17/27),OS-12为100%。⑤亚组分析发现该方案对男供者的cGVHD更有效,对治疗口腔、皮肤、肝脏cGVHD疗效较好。⑥不良反应:新发高脂血症3例,血糖升高1例,腹胀/腹泻4例,口腔溃疡2例,血尿1例,药物性肝损伤1例,细菌感染3例,真菌感染3例,带状疱疹2例,均为1~2级,无新增巨细胞病毒、EB病毒感染。 结论: 西罗莫司联合CNI治疗糖皮质激素耐药/依赖广泛型cGVHD的疗效及安全性较好,适合cGVHD的长期治疗。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhu W, Feng YM, Chen T, et al. [The clinical observation of sirolimus combined with calcineurin inhibitors for steroid-resistant/steroid-dependent extensive cGVHD]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 33113602. doi:10.3760/cma.j.issn.0253-2727.2020.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。